
样式: 排序: IF: - GO 导出 标记为已读
-
A Telacebec-shaped Puzzle Piece in the Treatment of Mycobacterial Diseases. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-13 Bouke B C de Jong
-
Little Big Issues in Brain-Lung Crosstalk. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-09 Ines Domínguez de la Cruz,Lluis Blanch,Guillermo M Albaiceta
-
Reply to Domínguez de la Cruz et al.: Little Big Issues in Brain-Lung Crosstalk. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-09 Dimitrios Georgopoulos
-
Clustering Pulmonary Hypertension Patients Using the Plasma Proteome. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-09 Athénaïs Boucly,Shanshan Song,Merve Keles,Dennis Wang,Luke S Howard,Marc Humbert,Olivier Sitbon,Allan Lawrie,A A Roger Thompson,Philipp Frank,Mika Kivimaki,Christopher J Rhodes,Martin R Wilkins
INTRODUCTION Patients with pulmonary hypertension are classified according to clinical criteria to inform treatment decisions. Knowledge of the molecular drivers of pulmonary hypertension might better inform treatment choice. METHODS Between 2013 and 2021, 470 patients with pulmonary hypertension, 136 disease controls and 59 healthy controls were enrolled as a discovery cohort. Plasma levels of 7288
-
Social Determinants of Health and Racial Disparities in Lung Function: Findings from NHANES 2007-2012. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-09 Amin Adibi,Christopher Carlsten,Emily P Brigham,Don D Sin,Peter Loewen,Mohsen Sadatsafavi
RATIONALE We hypothesized that the disproportionate impact of social determinants of health (SDoH) captured in survey data could help explain a larger proportion of racial gaps in lung function than previously reported. METHODS We defined a series of nested, increasingly healthy reference populations using data from NHANES 2007-2012. Starting with non-smokers without respiratory symptoms or diagnoses
-
Alveolar Collapse in ARDS Causes Severe Lung Damage, but What About Liquid Resuscitation? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-02 Bo Liu
-
Reply to Liu: Alveolar Collapse in ARDS Causes Severe Lung Damage, but What About Liquid Resuscitation? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-02 Mayson L A Sousa,Bhushan H Katira,Sheena Bouch,Vanessa Hsing,Doreen Engelberts,Marcelo B P Amato,Martin Post,Laurent J Brochard
-
Anomalous Azygos Continuation of the Inferior Vena Cava and Bifemoral Veno-Venous Extracorporeal Membrane Oxygenation. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-02 Lorenzo Giosa,Nicholas Ioannou,Carla Goncalves,Filippo Palmesino,Christopher I S Meadows
-
STAT3-dependent Regulation of CFTR and Ciliogenesis Is Essential for Mucociliary Clearance and Innate Airway Defense in Hyper-IgE Syndrome. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-02 Ling Sun,Samantha A Walls,Hong Dang,Nancy L Quinney,Patrick R Sears,Taraneh Sadritabrizi,Koichi Hasegawa,Kenichi Okuda,Takanori Asakura,Xiuya Chang,Meiqi Zheng,Yu Mikami,Felicia U Dizmond,Daniela Danilova,Lynn Zhou,Anshulika Deshmukh,Deborah M Cholon,Giorgia Radicioni,Troy D Rogers,William J Kissner,Matthew R Markovetz,Tara N Guhr Lee,Mark I Gutay,Charles R Esther,Michael Chua,Barbara R Grubb,Camille
RATIONALE Hyper IgE syndrome (STAT3-HIES), also known as Job's syndrome, is a rare immunodeficiency disease typically caused by dominant-negative STAT3 mutations. STAT3-HIES is characterized by chronic pulmonary infection and inflammation, suggesting impaired innate host defense. OBJECTIVES To identify airway epithelial host defense defects caused by STAT3 mutations that, together with immune dysfunction
-
Letting Cooler Heads Prevail: The Necessity of Occupational Regulation of Heat and Smoke Exposure. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-02 Maeve Georgia MacMurdo,Hasan Bayram,Emily Brigham,Daniel Croft,Gillian Goobie,Alison G Lee,Laura C Myers,Nicholas Nassikas,Jared Radbel
-
Reply to Tung et al.: Methodological Considerations in the Study of PRISm and Dementia Risk. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Jinyuan Wang,Yamei Tang
-
Methodological Considerations in the Study of PRISm and Dementia Risk. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Chung-Chu Tung,Wen-Bin Yeh,Renin Chang,Wei-Kai Lee
-
Considerations for Data Accuracy in Assessing PAH Care Delivery. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Chung-Chu Tung,Renin Chang
-
Reply to Tung and Chang and to Suntharalingam et al. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Samuel G Rayner,Rachel J Le,Peter J Leary,John Hartney,Nathan Hatton,John Ryan
-
Severe Hypoxemia and Pulmonary Capillary Dilatations in PAH Patients Treated with Sotatercept. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Karen M Olsson,Laurent Savale,Christophe Guignabert,Da-Hee Park,Jan C Kamp,Athénaïs Boucly,David Montani,Olivier Sitbon,Marc Humbert,Marius M Hoeper
-
Improving the Reporting of Trials Evaluating Organ-Support Therapies Using Multistate Modeling. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 David Hajage,Stéphane Gaudry,Alain Combes,Virginie Lemiale,Matthieu Schmidt,Jérôme Lambert
RATIONALE Managing critically ill patients in the ICU often involves organ-support therapies (OST), such as mechanical ventilation, extracorporeal membrane oxygenation, renal replacement therapy, and various pharmacologic strategies. Clinical trials in this context pursue diverse goals-including improving survival, reducing OST use, facilitating weaning, or comparing timing of OST initiation-which
-
How Can We Ensure Accessible and High-Quality Specialist Care for Pulmonary Hypertension Patients? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Jay Suntharalingam,Mark R Toshner,Kathy Blacker,Luke S Howard,David G Kiely
-
Reply to de Benedictis: Publication Bias: For How Much Longer? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Andrew Bush
-
From Repurposing to Refinement: Optimizing Levofloxacin for Treatment of MDR-TB. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Jae-Joon Yim
-
Camlipixant: A New Hope for Refractory Chronic Cough? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Imran Satia,Stuart B Mazzone
-
Carcinogenic Industrial Air Emissions and Lung Cancer Risk in a Cohort of 440,000 Americans. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Jessica M Madrigal,Jared A Fisher,Caroline N Pruitt,Linda M Liao,Barry I Graubard,Mary H Ward,Debra T Silverman,Rena R Jones
RATIONALE Industrial facilities emit known lung carcinogens into air, but the association of these agents with lung cancer risk at environmental levels is unknown. OBJECTIVES To investigate industrial emissions and lung cancer risk. METHODS We used a U.S. regulatory database to estimate airborne exposure to known and probable human carcinogens (N=31) emitted from industrial sources (1987-1995) for
-
The Other Side of the Coin of Pulmonary Fungal Diseases: Towards New Paradigms. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Manuel Castillejos López,David Martínez Briseño
-
Dulling the Double-edged Sword: Expanding the Arsenal of Diaphragm Protection in Early Respiratory Failure. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Heder de Vries,Timothy Girard
-
Another Act in the Story of Oral Imatinib for PAH. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Mardi Gomberg-Maitland,Rogerio Souza
-
Post-TB Sequelae and the Burden of "Long TB": Continuing TB Care after Treatment Completion. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Sara C Auld,Gregory P Bisson
-
Simplifying Sotatercept in Pulmonary Arterial Hypertension: Genetic Context Meets Treatment-Response. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Bradley A Maron
-
Publication Bias: For How Much Longer? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-30 Fernando M de Benedictis
-
The Resilience of the Human Lungs: Evolution, Smoke, and Disease. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-23 Joan B Soriano,Francesca Polverino
-
Risk Factors for Patient-Important Upper Gastrointestinal Bleeding. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-18 Adam M Deane,François Lauzier,Neill K J Adhikari,François Lamontagne,Diane Heels-Ansdell,Lehana Thabane,David Williamson,Salmaan Kanji,Jeffrey F Barletta,Simon Finfer,Yaseen Arabi,Marlies Ostermann,John C Marshall,Nicole L Zytaruk,Miranda Hardie,Naomi E Hammond,Gordon Guyatt,Kyle C White,Karen E A Burns,Joanna C Dionne,Paul J Young,Deborah J Cook,
RATIONALE Patient-important gastrointestinal bleeding is an endpoint developed by patients and family members; however, risk factors for this outcome are unknown. OBJECTIVE To identify risk factors for patient-important upper gastrointestinal bleeding among invasively ventilated adults. METHODS This pre-planned regression analysis of an international trial database evaluated baseline and time-varying
-
Development of New Intrapulmonary Shunts in Pulmonary Arterial Hypertension Treated with Sotatercept. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-17 Stephen Mitchell,Romina Gomez,Akshay Mathavan,Akash Mathavan,Saminder Kalra,Andrew Bryant,Ali Ataya
-
Associations of Pre-Pandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-16 Pallavi P Balte,John S Kim,Yifei Sun,Nori Allen,Elsa Angelini,Alexander Arynchyn,R Graham Barr,Michael Blaha,Russell Bowler,Jeff Carr,Shelley A Cole,David Couper,Ryan T Demmer,Margaret Doyle,Mitchell Elkind,Raúl San José Estépar,Olga Garcia-Bedoya,Suresh Garudadri,Nadia N Hansel,Emilia A Hermann,Eric A Hoffman,Stephen M Humphries,Gary M Hunninghake,Robert Kaplan,Jerry A Krishnan,Andrew Laine,Joyce
RATIONALE Increased risk of COVID-19 hospitalization and death has been reported among patients with clinical lung disease. OBJECTIVE To test the association of objective measures of pre-pandemic lung function and structure with COVID-19 outcomes in US adults. METHODS Pre-pandemic obstruction (FEV1/FVC<0.70) and restriction (FEV1/FVC≥0.7, FVC<80%) were defined based on the most recent spirometry exam
-
Adjusting the P/F-Ratio for BMI in Acute Hypoxemic Respiratory Failure Mitigates but Does Not Eliminate the Obesity Paradox. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-16 Philipp Simon,David Petroff,Andrew J Simpkin,Tài Pham,Giacomo Bellani,John G Laffey,Hermann Wrigge
-
Reply to Rui et al.: Assessing the Correlation Between Systemic Inflammation and GGO: Beyond a Single Indicator. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Spyridon Fortis,Alejandro P Comellas
-
The Impact of Comorbidities on Serum IgG Levels and Exacerbation Risk in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Hajime Fujimoto,Taro Yasuma,Corina N D'Alessandro-Gabazza,Esteban C Gabazza,Osamu Hataji,Tetsu Kobayashi
-
Reply to Chen et al. and to Fujimoto et al. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Michael Burnim,Nadia N Hansel,Nirupama Putcha
-
Assessing the Correlation Between Systemic Inflammation and GGO: Beyond a Single Indicator. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Rui Zhang,Xi Xi Chen,Jian Ping Zhou,Qing Yun Li
-
Lower Immunoglobulin G Levels Increased Exacerbation Risk in COPD: New Insights for Clinical Practice. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Yen-Fu Chen,Jung-Yien Chien,Hao-Chien Wang,Chong-Jen Yu
-
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Cori L Daines,Deepika Polineni,Elizabeth Tullis,Stefano Costa,Rachel W Linnemann,Marcus A Mall,Edward F McKone,Bradley S Quon,Felix C Ringshausen,Hiran Selvadurai,Jennifer L Taylor-Cousar,Nicholas J Withers,Gregory S Sawicki,Timothy Lee,Neil Ahluwalia,Jessica Morlando Geiger,Mark Jennings,Yaoyuan Vincent Tan,David Waltz,Bonnie Ramsey,Matthias Griese,
RATIONALE Clinical and real-world studies show elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is efficacious and safe in people with cystic fibrosis (CF) ≥12 years of age with at least one F508del allele. OBJECTIVES Given the potential for life-long ELX/TEZ/IVA use, long-term safety and efficacy of ELX/TEZ/IVA was assessed. METHODS In this phase 3, open-label, single-arm extension study, participants
-
Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease: The TASC Randomized Clinical Trial. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Armand Mekontso Dessap,Anoosha Habibi,Jean-Benoît Arlet,Muriel Fartoukh,Laurent Guerin,Constance Guillaud,Damien Roux,Johanna Oziel,Stéphanie Ngo,Benjamin Carpentier,Marilucy Lopez-Sublet,Louis Affo,Giovanna Melica,Maryse Etienne-Julan,Isabelle Delacroix,François Lionnet,Gylna Loko,Daniel Da Silva,Marc Michel,Keyvan Razazi,Anaïs Charles-Nelson,Pablo Bartolucci,Ségolène Gendreau,Sandrine Katsahian,Bernard
BACKGROUND Patients with sickle cell disease hospitalised for acute chest syndrome (ACS) are at high risk of in situ pulmonary microthrombosis. We evaluated whether therapeutic anticoagulation could shorten ACS duration. METHODS TASC is a randomized, controlled, double-blind trial conducted in 12 French hospitals (December 2016-April 2021) in adult ACS patients with no initial thrombosis on chest computerised
-
A Twist in the Fibrotic Tale: The Overlooked Vasculopathy in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Adriano R Tonelli,Sandeep Sahay
-
Argon Plasma Coagulation Combined with Human Fibrin Sealant under Medical Thoracoscopy in the Closure of Bronchopleural Fistula. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Rui Xu,Kaige Wang,Weimin Li,Dan Liu
-
A New Target from a Target Trial Emulation: Allow Early Assisted Breathing. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Andrew J Admon,Christopher J Yarnell
-
Proteomic Biomarkers of Survival in Non-IPF Interstitial Lung Disease. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Shehabaldin Alqalyoobi,Jennifer A Smith,Manoj V Maddali,Janelle Vu Pugashetti,Chad A Newton,John S Kim,Angela L Linderholm,Ching-Hsien Chen,Shwu-Fan Ma,Swaraj Bose,Susan Murray,Ayodeji Adegunsoye,Mary E Strek,Christine Kim Garcia,Paul J Wolters,Fernando J Martinez,Imre Noth,Justin M Oldham
RATIONALE While idiopathic pulmonary fibrosis (IPF) has been widely studied, progressive non-IPF interstitial lung disease (ILD) remains poorly understood. OBJECTIVE To identify and validate proteomic biomarkers of non-IPF ILD survival. METHODS High-throughput proteomic data were generated using plasma collected as part of prospective registries at the Universities of California and Texas (discovery
-
Association of Delirium with Increased Risk of Mild Cognitive Impairment and Alzheimer's Disease and Related Dementias. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Yubo Feng,Chao Yan,Yuankai Huo,Bingshan Li,Zhongliang Zu,Michael C Smith,Mayur B Patel,You Chen
-
Beyond Binary: The Potential of Ordinal Outcomes in Critical Care Trials. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-10 Kelsey Hills-Dunlap,Marc Moss
-
Reply to Currow et al. and to Akgün. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 Amy Heinzerling,Robert Harrison,Jennifer Flattery,Jane C Fazio,Sheiphali Gandhi,Kristin J Cummings
-
Combating Global Silicosis Epidemics: Can We Alter Sisyphus's Fate? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 Metin Akgün
-
We'll Look Back and Say, "Why Didn't We Act Sooner on Engineered Stone?''. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 David C Currow,Kate F Cole,Sanchia K Aranda,Malcolm R Sim
-
Reply to Martin-Loeches and Rodriguez: Clinical Guidelines: Asking the Right Questions to Guide Fungal Infection Management. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 Oleg Epelbaum,Tina Marinelli,Kelly M Pennington,Andrew H Limper,Chadi A Hage
-
Clinical Guidelines: Asking the Right Questions to Guide Fungal Infection Management. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 Ignacio Martin-Loeches,Alejandro H Rodriguez
-
Clinician Prediction of Hyperinflammatory ARDS Subphenotypes: Overestimated but Prognostic. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 Georgios D Kitsios,Menaal Haque,William G Bain,Charles Dela Cruz,Bryan J McVerry,Faraaz A Shah,
-
Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 Ying Xia,Weiwei Jiang,Xinlin Zhu,Bo Pan,Tianyang Chen,Yan Wang,Wanqing Liao,Weihua Pan
Rationale: The lungs are the most prevalent site for invasive fungal infections, and the diagnosis and treatment of pulmonary fungal infections pose significant challenges, accompanied by a substantial disease burden. Global factors will likely enhance the risk of it in the future. Assessing the global burden of pulmonary fungal infections is crucial for implementing appropriate measures for prevention
-
Oscillometry-defined Small Airway Dysfunction in Tobacco-exposed Adults with Impaired or Preserved Airflow. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 Mustafa Abdo,Henrik Watz,Frederik Trinkmann,Sabine Bohnet,Miriam Annabella Marcella Guess,Johannes Roeben,Katharina May,Martin Reck,Benjamin-Alexander Bollmann,Susanne Stiebeler,Sabine Dettmer,Benjamin Waschki,Klaus F Rabe,Klaas Frederik Franzen,Jens Vogel-Claussen
RATIONALE Small airway dysfunction (SAD) is a key feature of COPD and might present in tobacco-exposed adults with normal spirometry. So far, the role of oscillometry-defined SAD in this population is largely unexplored. OBJECTIVE To investigate the prevalence of oscillometry-defined SAD and its associations with airway structural changes, quality of life (QoL), metabolic and cardiovascular disease
-
Unusual Presentation of Clear Cell Tumor of the Lung as Irregular Nodules with a Thin-walled Cavity. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 Minli Lv,Qiang Gao,Jianquan Zhong
-
Credible Subgroup Effects in Randomized Clinical Trials. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-02 Harm-Jan de Grooth,Nadir Yehya,Michael O Harhay
-
Navigating the Progression of Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-04-01 Carrie Pistenmaa,George R Washko
-
Reply to Hsiao and Chen: Refining the Concept of Disease Stability in COPD: Bridging Complexity and Clinical Practice. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-03-28 Dave Singh
-
Refining the Concept of Disease Stability in COPD: Bridging Complexity and Clinical Practice. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-03-28 Yi-Han Hsiao,Yen-Fu Chen
-
Right Ventricular Strain and Outflow Tract Velocity Time Integral Are Associated with Mortality in Critically Ill Patients with Pulmonary Embolism. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-03-28 Manuel Ruiz-Bailén,Javier Hidalgo-Martín,José Ángel Ramos Cuadra,Julia Manetsberger,Maria Dolores Pola Gallego de Guzmán,Miguel Ángel Díaz-Castellanos,Patricia Casado-Santa-Bárbara,Johannes Dagomar Lohman,Antonio Cárdenas-Cruz,Fernando Clau-Terré,María Leyre Lavilla-Lerma
INTRODUCTION High-risk pulmonary thromboembolism (PE) is often fatal due to right ventricular heart failure. However, right ventricular echocardiographic parameters that are associated with adverse outcome in PE are incompletely characterized. Our objective was to evaluate if right ventricular global longitudinal strain (RVGLS) and right ventricular outflow tract velocity-time integral (RVOT VTI) might
-
Development of a New Longitudinal Ordinal Outcome for Clinical Trials in ECMO Patients. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-03-28 Ary Serpa Neto,Lisa Higgins,Elizabeth Lorenzi,Lindsay Berry,Elizabeth Ryan,Stephane Heritier,Shannah Anderson,Judit Orosz,Aidan Burrell,Zoe McQuilten,Priya Nair,Carol L Hodgson
RATIONALE Randomised clinical trials in intensive care often prioritize disease-focused outcomes rather than patient-centred outcomes. OBJECTIVE To report and evaluate the 'Daily Organ Support for patients on extracorporeal membrane oxygenation (ECMO)', the DOSE outcome. This is a new longitudinal ordinal outcome for clinical trials in patients receiving ECMO. METHODS Prospective, multicentre study